Discussing PsA: Difficult-to-manage PsA and molecular/clinical responses to zasocitinib

Join Professor Laura Coates and Professor Philip Mease as they discuss recent publications that explored treatment-refractory PsA through real-world EULAR-informed definitions and the longitudinal effects of zasocitinib on TYK2 signalling, inflammation, skin and joint disease, tissue turnover, and clinical response.